BACKGROUND: The immunosuppressive therapy a patient requires to sustain a functioning renal allograft in the long term is associated with various skin complications. While quality of life (QoL) after renal transplantation has been studied, no publications document the effect of post-transplant dermatological complications on QoL. OBJECTIVES: The objective of the study was to document the prevalence of the skin diseases that commonly occur in association with post-transplant immunosuppression. A general dermatological quality of life questionnaire, the Dermatology Life Quality Index (DLQI), was used to assess the QoL effect of these cutaneous complications. The study was designed to examine further the impact of age, sex, duration since transplant and immunosuppressive regimen on the DLQI score of renal transplant recipients (RTR). METHODS: One hundred and seventy-three RTR completed the DLQI, were interviewed and examined for evidence of common post-transplant skin diseases. RESULTS: Sixteen per cent of RTR had DLQI scores >6, reflecting a significant impact on their QoL. Dry skin, itch, hypertrichosis, sebaceous gland hyperplasia, acne, genital warts and a history of >4 herpes simplex virus type 1 infections in the past year were all found to have a significant impact on the quality of life (P < 0.05). Multivariate analysis revealed that the greatest impact on QoL was in RTR who were younger, female and with multiple skin problems (P < 0.05). CONCLUSIONS: The dermatological complications of immunosuppressive therapy are common in RTR and can significantly impair QoL in certain individuals. Visible, infectious and cosmetic skin problems had most impact on QoL while a history of skin cancer had a lesser impact. Early dermatological referral and careful choice of immunosuppression may enhance the QoL, particularly in young and female RTR.
BACKGROUND: The immunosuppressive therapy a patient requires to sustain a functioning renal allograft in the long term is associated with various skin complications. While quality of life (QoL) after renal transplantation has been studied, no publications document the effect of post-transplant dermatological complications on QoL. OBJECTIVES: The objective of the study was to document the prevalence of the skin diseases that commonly occur in association with post-transplant immunosuppression. A general dermatological quality of life questionnaire, the Dermatology Life Quality Index (DLQI), was used to assess the QoL effect of these cutaneous complications. The study was designed to examine further the impact of age, sex, duration since transplant and immunosuppressive regimen on the DLQI score of renal transplant recipients (RTR). METHODS: One hundred and seventy-three RTR completed the DLQI, were interviewed and examined for evidence of common post-transplant skin diseases. RESULTS: Sixteen per cent of RTR had DLQI scores >6, reflecting a significant impact on their QoL. Dry skin, itch, hypertrichosis, sebaceous gland hyperplasia, acne, genital warts and a history of >4 herpes simplex virus type 1 infections in the past year were all found to have a significant impact on the quality of life (P < 0.05). Multivariate analysis revealed that the greatest impact on QoL was in RTR who were younger, female and with multiple skin problems (P < 0.05). CONCLUSIONS: The dermatological complications of immunosuppressive therapy are common in RTR and can significantly impair QoL in certain individuals. Visible, infectious and cosmetic skin problems had most impact on QoL while a history of skin cancer had a lesser impact. Early dermatological referral and careful choice of immunosuppression may enhance the QoL, particularly in young and female RTR.
Authors: Christina Lee Chung; Kumar S Nadhan; Christine M Shaver; Lauren M Ogrich; Mark Abdelmalek; Carrie Ann Cusack; Gregory E Malat; Ellen N Pritchett; Alden Doyle Journal: JAMA Dermatol Date: 2017-06-01 Impact factor: 10.282
Authors: Melvin Frie; Coby Annema; Emily S X Knijff; Stephan J L Bakker; Adelita V Ranchor; Michele F Eisenga; Emöke Rácz Journal: JAMA Dermatol Date: 2020-04-01 Impact factor: 10.282
Authors: Piotr K Krajewski; Kinga Tyczyńska; Klaudia Bardowska; Piotr Olczyk; Magdalena Krajewska; Jacek C Szepietowski Journal: Toxins (Basel) Date: 2022-04-30 Impact factor: 5.075
Authors: H Ghaninejad; A H Ehsani; M Ghiasi; P Noormohammadpour; E Najafi; G Naderi; M Ganji; M Mirnezami; R Nezami; P Kiani Journal: Indian J Dermatol Date: 2009-07 Impact factor: 1.494
Authors: Michela Castello; Marilena Gregorini; Teresa Rampino; Francesca Bosio; Giulia Bedino; Giovanni Piotti; Grazia Soccio; Pasquale Esposito; Catherine Klersy; Massimo Abelli; Giovanni Borroni; Antonio Dal Canton Journal: Indian J Med Res Date: 2013-06 Impact factor: 2.375
Authors: M de Troya-Martín; F Rivas-Ruiz; N Blázquez-Sánchez; I Fernández-Canedo; M Aguilar-Bernier; J B Repiso-Jiménez; J C Toribio-Montero; M Jones-Caballero; J Rhee Journal: J Skin Cancer Date: 2016-10-09